<DOC>
	<DOCNO>NCT01032655</DOCNO>
	<brief_summary>Background : Helicobacter pylori infection show associate development gastric cancer peptic ulcer disease . Eradication H. pylorus infection could reduce occurence recurrence disease . However , estimate 15-20 % patient would fail first line standard eradication therapy need second line rescue therapy . About 15-30 % patient would fail second line therapy need rescue third line therapy . The commonly used salvage regimen include ( 1 ) Bismuth base quadruple therapy ( combine ranitidine PPI plus two antibiotic ) ( 2 ) Levofloxacin moxifloxacin rifabutin base triple therapy . However , Bismuth available many country administration method complex . Its usage limited high pill number low compliance rate . In recent year , concept sequential therapy advocate treatment H. pylorus infection . The regimen include PPI plus amoxicillin five day , follow PPI plus clarithromycin metronidazole another five day . The eradication rate first line treatment sequential therapy report high 90 % . More importantly , demonstrate eradication rate among patient clarithromycin-resistant strain could high 89 % . According Maastricht III consensus meeting , recommend susceptibility test do patient fail two treatment . Therefore , aim assess efficacy susceptibility test drive sequential therapy third line therapy fail two standard eradication therapy . Methods : This multi-center , open label pilot study 1 . Patients : - Open label , non-comparative pilot study 2 . Testing H. pylori infection : - Before salvage treatment : either ( 1 ) two positive CLO test , histology , culture ( 2 ) positive C13-UBT consider failure previous eradication treatment EGD gastric biopsy do H. pylori culture susceptibility test - After salvage treatment : C13-UBT used ass existence H. pylori 2nd 3rd line salvage therapy 3 . Treatment regimens assignment : - D1-7 : Nexium ( 40 mg , bid ) , Amolin ( 1 gm , bid ) - D8-14 : Nexium ( 40 mg , bid ) , Flagyl ( 500 mg , bid ) plus either one follow accord antibiotic susceptibility test ( 1 ) Klaricid , 500 mg , bid ( 2 ) Cravit , 250 mg , bid ( 3 ) Tetracycline , 500 mg , bid 4 . Outcome Measurement : - Primary End Point : Eradication rate evaluate accord Intent-to-treat ( ITT ) per-protocol ( PP ) analyse - Secondary End Point : eradication rate accord antibiotic susceptibility salvage therapy</brief_summary>
	<brief_title>The Efficacy Susceptibility Test -Driven Sequential Therapy Third Line Therapy Refractory Helicobacter Pylori Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Disease Susceptibility</mesh_term>
	<mesh_term>Helicobacter Infections</mesh_term>
	<criteria>1. age great 20 year persistent H. pylorus infection two treatment willing receive third line rescue regimen . 1. child teenager age less 20 year , 2. history gastrectomy , 3. gastric malignancy , include adenocarcinoma lymphoma , 4. previous allergic reaction antibiotic ( Amolin , Klaricid , Cravit ) prompt pump inhibitor ( esomeprazole ) , 5. contraindication treatment drug , 6. pregnant lactate woman , 7. severe concurrent disease .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Helicobacter pylorus</keyword>
	<keyword>sequential therapy</keyword>
	<keyword>susceptibility-driven</keyword>
	<keyword>rescue</keyword>
	<keyword>levofloxacin</keyword>
	<keyword>clarithromycin</keyword>
	<keyword>salvage</keyword>
	<keyword>treatment failure</keyword>
	<keyword>fail two standard eradication therapy</keyword>
</DOC>